反应停联合FOLFOX方案治疗晚期消化道癌临床研究

目的：评价反应停联合FOLFOX方案治疗晚期消化道癌的近期疗效和毒副反应。方法：28例晚期消化道癌患者,先给予草酸铂（L-OHP）85mg/m2静脉点滴2hd1,亚叶酸钙（CF）200mg/m2静脉点滴2hd1-d2,随后5-氟脲嘧啶（5-FU）400mg/m2静脉推注,5-FU600mg/m2静脉点滴22hd1-d2,同时给予口服反应停200mg/Dd1-d10。2周重复,4周期后评价疗效。结果：全组28例,其中完全缓解（CR）2例（7.1%）,部分缓解（PR）16例（57.1%）,稳定（SD）4例（14.3%）,进展（PD）6例（21.4%）。总有效率（CR＋PR）64.3%。胃癌16例,11例有效,有效率68.8%。大肠癌12例,7例有效,有效率58.3%。毒副反应主要是恶心呕吐,白细胞减少,神经感觉毒性,无化疗相关死亡。结论：反应停联合FOLFOX方案治疗晚期消化道癌疗效肯定,毒副反应能耐受。

Clinical Study of Thalidomide Combined with Biweekly Regimen of Leucovorin,5-Fluorouracil and Oxaliplatin in Treatment of Advanced Alimentary Canal Cancer

Objective：To study the response and toxicity of the regimen of thalidomide combined with biweekly regimen of leucovorin（CF）,5-fluorouracil（5-FU）and oxaliplatin（L-OHP）in treatment of advanced alimentary canal cancer.Methods：28 patients with advanced alimentary canal cancer received chemotherapy of regimen L-OHP 80mg/m2 2 hours iv on day1,CF 200 mg/m2 2 hours iv on day 1to 2,followed by 5-FU 400 mg/m2 iv Bolus and 600 mg/m2 22 hours on day 1to 2.Thalidomide 200mg/D po on day 1 to 10,two weeks as one cycle.Efficacy was evaluated at 4 cycles.Results：2 patients achieved complete response（CR）,16 patients partial response（PR）,4 patients stable disease（SD）,6 patients progression disease（PD）.Overall response rate was 64.3%.Response rate was 68.8% in advanced gastric cancer.Response rate was 58.3% in advanced colorectal cancer.The major toxicity included nausea,vomiting,leucopenia and neuro-sensory.There were no any death events during treatment.Conclusion：This study shows that the regimen of thalidomide combined with FOLFOXis effective and tolerable in advanced alimentary canal cancer.